Finland-based DelSiTech has signed a world-wide, exclusive license agreement with Innovare R&D, a Mexico-based pharma company, it was reported yesterday.

The contract has been signed for the use of the former's Silica Matrix drug delivery platform in the development and commercialisation of a long acting HIV therapy.

According to the terms of the agreement, Innovare will use DelSiTech's technology on its peptide membrane fusion inhibitor, targeting the envelope protein of human immunodeficiency virus-1. DelSiTech is entitled to receive an upfront payment, milestone payments and royalties on development, commercialisation and sales of the Silica Matrix formulated T1144 drug product. Financial details of the deal were not revealed.